New therapies are changing what is possible in generalised myasthenia gravis care, yet unequal access across Europe continues to hold patients back. Better diagnosis, specialist referral and more consistent access to care could improve outcomes while supporting health system resilience, workforce participation and economic sustainability.
Generalised myasthenia gravis (gMG) may be a rare disease, but the questions it raises for Europe’s healthcare systems are increasingly urgent: how quickly can medical innovation reach patients, and how can access be delivered evenly across countries and communities?
For people living with gMG the stakes are high. gMG is a chronic, autoantibody disease that causes fluctuating and potentially severe muscle weakness.1, 2 Symptoms can affect speech, swallowing, mobility and, in some cases, respiratory function.3 While there is still no cure, advances in treatment are transforming expectations for disease management and quality of life.
This marks an important shift in care. For decades, many patients faced unpredictable disease progression and significant disruption to daily life.4, 5, 6, 7 Today, effective management and improved functional outcomes are becoming a more achievable goal for many people living with gMG.8 Yet these advances only matter if patients can reach them in practice.
